Publications by authors named "R Serna-Blasco"
This review aims to summarize recent studies and findings within adoptive cell therapies, including tumor-infiltrating lymphocytes, genetically engineered T cell receptors, and chimeric antigen receptor T cells, in the treatment of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, and malignant pleural mesothelioma. Several trials are ongoing, and a few have reported results, suggesting that adoptive cell therapies may represent a potential treatment option for these patients, especially when checkpoint inhibition has failed. We also discuss the potential implementation of these therapies, as they present a new toxicity profile and an intrinsic financial burden.
View Article and Find Full Text PDFArticle Synopsis
- - The NADIM trial was a phase 2 study in Spain that evaluated the effects of perioperative immunotherapy on long-term outcomes in patients with stage IIIA non-small-cell lung cancer (NSCLC), showing positive short-term results previously. - A total of 46 treatment-naive patients participated, receiving a combination of chemotherapy and nivolumab before surgery, followed by more nivolumab as adjuvant therapy, with the study measuring 5-year progression-free and overall survival rates. - Findings showed that after 5 years, 65% of patients were progression-free and 69% had overall survival, with disease progression seen in 24% of patients and 30% dying by the end of the follow-up period.
Article Synopsis
- Immunotherapy treatments show high effectiveness in advanced non-small-cell lung cancer (NSCLC), but the impact of BRAF mutations in these cases is unclear.
- In a study of 116 stage IIIA/B and 84 stage IV patients, BRAF mutations were found in a small percentage, with all patients who had these mutations remaining alive and disease-free at the study's cutoff.
- BRAF-mutated patients had a 100% pathological complete response rate to neoadjuvant chemoimmunotherapy compared to a 44.3% rate in BRAF wild-type patients, suggesting that BRAF mutations could indicate better outcomes for those undergoing immunotherapy.
Background: Approximately 20% of patients with non-small-cell lung cancer (NSCLC) receive a diagnosis of stage III disease. There is no current consensus regarding the most appropriate treatment for these patients.
Methods: In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) or chemotherapy alone (control group), followed by surgery.
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
JAMA Oncol
March 2023
Importance: Antiangiogenic drug combinations with anti-programmed cell death 1 protein and anti-programmed cell death 1 ligand 1 (PD-L1) agents are a novel treatment option for lung cancer. However, survival remains limited, and the activity of these combinations for tumors with high tumor mutation burden (TMB) is unknown.
Objective: To assess the clinical benefits and safety of atezolizumab plus bevacizumab for patients with high-TMB advanced nonsquamous non-small cell lung cancer (NSCLC).